Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kayo Yoshida is active.

Publication


Featured researches published by Kayo Yoshida.


International Journal of Radiation Oncology Biology Physics | 2011

Dose Constraint for Minimizing Grade 2 Rectal Bleeding Following Brachytherapy Combined With External Beam Radiotherapy for Localized Prostate Cancer: Rectal Dose-Volume Histogram Analysis of 457 Patients

Yutaka Shiraishi; Atsunori Yorozu; Toshio Ohashi; Kazuhito Toya; Satoshi Seki; Kayo Yoshida; Tomoya Kaneda; Shiro Saito; Toru Nishiyama; Takashi Hanada; Naoyuki Shigematsu

PURPOSE To determine the rectal tolerance to Grade 2 rectal bleeding after I-125 seed brachytherapy combined with external beam radiotherapy (EBRT), based on the rectal dose-volume histogram. METHODS AND MATERIALS A total of 458 consecutive patients with stages T1 to T3 prostate cancer received combined modality treatment consisting of I-125 seed implantation followed by EBRT to the prostate and seminal vesicles. The prescribed doses of brachytherapy and EBRT were 100 Gy and 45 Gy in 25 fractions, respectively. The rectal dosimetric factors were analyzed for rectal volumes receiving >100 Gy and >150 Gy (R100 and R150) during brachytherapy and for rectal volumes receiving >30 Gy to 40 Gy (V30-V40) during EBRT therapy in 373 patients for whom datasets were available. The patients were followed from 21 to 72 months (median, 45 months) after the I-125 seed implantation. RESULTS Forty-four patients (9.7%) developed Grade 2 rectal bleeding. On multivariate analysis, age (p = 0.014), R100 (p = 0.002), and V30 (p = 0.001) were identified as risk factors for Grade 2 rectal bleeding. The rectal bleeding rate increased as the R100 increased: 5.0% (2/40 patients) for 0 ml; 7.5% (20/267 patients) for >0 to 0.5 ml; 11.0% (11/100 patients) for >0.5 to 1 ml; 17.9% (5/28 patients) for >1 to 1.5 ml; and 27.3% (6/22 patients) for >1.5 ml (p = 0.014). Grade 2 rectal bleeding developed in 6.4% (12/188) of patients with a V30 ≤35% and in 14.1% (26/185) of patients with a V30 >35% (p = 0.02). When these dose-volume parameters were considered in combination, the Grade 2 rectal bleeding rate was 4.2% (5/120 patients) for a R100 ≤0.5 ml and a V30 ≤35%, whereas it was 22.4% (13/58 patients) for R100 of >0.5 ml and V30 of >35%. CONCLUSION The risk of rectal bleeding was found to be significantly volume-dependent in patients with prostate cancer who received combined modality treatment. Rectal dose-volume analysis is a practical method for predicting the risk of development of Grade 2 rectal bleeding.


Japanese Journal of Clinical Oncology | 2013

Comparison of Preplanning and Intraoperative Planning for I-125 Prostate Brachytherapy

Kayo Yoshida; Toshio Ohashi; Atsunori Yorozu; Kazuhito Toya; Toru Nishiyama; Shiro Saito; Takashi Hanada; Yutaka Shiraishi; Naoyuki Shigematsu

OBJECTIVE To compare two widely used permanent prostate brachytherapy techniques, preplanning and intraoperative planning, based on postimplant dosimetry, toxicity and biochemical outcomes. METHODS Between 2003 and 2006, 665 men with localized prostate cancer were treated with permanent interstitial implantation. The first 227 consecutive men were treated with the preplanning technique, followed by 438 men treated with the intraoperative technique. Late toxicity was scored by the Common Terminology Criteria for Adverse Events v.4.0. Biochemical failure was defined as a prostate-specific antigen increase of more than 2 ng/ml above the nadir value excluding a benign bounce. Univariate and multivariate analyses were performed to identify the variables associated with biochemical failure-free survival. RESULTS Postimplant target coverage was similar in the two groups, with a small difference in risk organ doses. Mean V100 was 96.3 vs. 96.7% (P = 0.205), D90 was 119.6 vs. 119.4% (P = 0.884), urethral D10 was 157.5 vs. 146.1% (P = 0.010), rectal V100 was 0.57 vs. 0.43 cc (P = 0.002) in the preplanning and intraoperative planning groups, respectively. Acute and late Grade 3 genitourinary and gastrointestinal toxicities were <1% for both methods. The 5-year biochemical failure-free survival rate was 95.4% for the preplanning and 94.0% for the intraoperative planning group (P = 0.776). Multivariate analysis revealed Gleason score, biopsy positive rate and V100 to be predictors of biochemical failure-free survival, while the planning technique was not significant. CONCLUSION This large-scale analysis of high-quality implants revealed similar postimplant dosimetry, toxicity profiles and biochemical failure-free survival for the preplanning and intraoperative planning methods.


International Journal of Clinical Oncology | 2014

Five-year potency preservation after iodine-125 prostate brachytherapy.

Shuichi Nishimura; Atsunori Yorozu; Toshio Ohashi; Masanori Sakayori; Yasuto Yagi; Toru Nishiyama; Shiro Saito; Yutaka Shiraishi; Kayo Yoshida; Kazuhito Toya; Naoyuki Shigematsu


Brachytherapy | 2016

Single-energy metal artifact reduction in postimplant computed tomography for I-125 prostate brachytherapy: Impact on seed identification.

Yutaka Shiraishi; Yoshitake Yamada; Tomoki Tanaka; Takahisa Eriguchi; Shuichi Nishimura; Kayo Yoshida; Takashi Hanada; Toshio Ohashi; Naoyuki Shigematsu; Masahiro Jinzaki


Journal of Gastrointestinal Surgery | 2018

Postoperative Pneumonia is Associated with Long-Term Oncologic Outcomes of Definitive Chemoradiotherapy Followed by Salvage Esophagectomy for Esophageal Cancer

Masashi Takeuchi; Hirofumi Kawakubo; Shuhei Mayanagi; Kayo Yoshida; Kazumasa Fukuda; Rieko Nakamura; Koichi Suda; Norihito Wada; Hiroya Takeuchi; Yuko Kitagawa


Gastrointestinal Endoscopy | 2018

Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancer

Masashi Takeuchi; Koichi Suda; Yasuo Hamamoto; Motohiko Kato; Shuhei Mayanagi; Kayo Yoshida; Kazumasa Fukuda; Rieko Nakamura; Norihito Wada; Hirofumi Kawakubo; Hiroya Takeuchi; Naohisa Yahagi; Yuko Kitagawa


International Journal of Radiation Oncology Biology Physics | 2013

Dose Escalation Impacts Biochemical Outcomes of Inadequate PSA Nadir During Neoadjuvant Hormone Therapy Before Brachytherapy for Intermediate-Risk Prostate Cancer

Atsunori Yorozu; Shiro Saito; Kazuhito Toya; Kayo Yoshida; A. Takahashi; Tomoki Tanaka; N. Kuroiwa; Yutaka Shiraishi; Toshio Ohashi


Brachytherapy | 2013

D90S Predicting Biochemical Tumor Control after 125I Prostate Brachytherapy: Effects of Day 1 and Day 30 Dosimetry and a Prostate Margin

Atsunori Yorozu; Shiro Saito; Kazuhito Toya; Kayo Yoshida; Akane Takahashi; Yasuto Yagi; Toru Nishiyama; Shuichi Nishimura; Masanori Sakayori


Japanese journal of clinical radiology | 2012

PSA nadir after 125I prostate brachytherapy

Atsunori Yorozu; Kazuhito Toya; Kayo Yoshida; N. Koike; Akane Takahashi; S. Saito; Toru Nishiyama; Yasuto Yagi; Ryo Namitome; Asuka Ashikari; T. Kono


International Journal of Radiation Oncology Biology Physics | 2012

A Dose-response Analysis of Biochemical Control and Toxicity for I-125 Prostate Brachytherapy

Atsunori Yorozu; Shiro Saito; Kazuhito Toya; Kayo Yoshida

Collaboration


Dive into the Kayo Yoshida's collaboration.

Top Co-Authors

Avatar

Kazuhito Toya

International University of Health and Welfare

View shared research outputs
Top Co-Authors

Avatar

Atsunori Yorozu

Jikei University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Shiro Saito

University of Tokushima

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge